{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:54:33Z","timestamp":1760576073809,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.numecd.2021.05.019","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T11:20:26Z","timestamp":1622028026000},"page":"2354-2357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clearing hepatitis C virus with direct antiviral agents reduces cardiovascular events in patients with prediabetes. Commentary to Sasso and colleagues"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9886-0698","authenticated-orcid":false,"given":"Amedeo","family":"Lonardo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7271-6329","authenticated-orcid":false,"given":"Alessandro","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2021.05.019_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","volume":"14","author":"Thrift","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2021.05.019_bib2","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/liv.14808","article-title":"The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries","volume":"41","author":"Mennini","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.numecd.2021.05.019_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.numecd.2021.05.019_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1586\/eri.09.3","article-title":"Hepatitis C and diabetes: the inevitable coincidence?","volume":"7","author":"Lonardo","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.numecd.2021.05.019_bib5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2012.01.051","article-title":"Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis","volume":"221","author":"Adinolfi","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2021.05.019_bib6","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.3748\/wjg.v22.i44.9674","article-title":"Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - evidence from three different disease models: NAFLD, HCV and HIV","volume":"22","author":"Lonardo","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.numecd.2021.05.019_bib7","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/liv.13064","article-title":"Chronic hepatitis C virus infection, a new cardiovascular risk factor?","volume":"36","author":"Domont","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.numecd.2021.05.019_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ahj.2017.10.024","article-title":"Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients","volume":"198","author":"Cacoub","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.numecd.2021.05.019_bib9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/liv.13272","article-title":"The impact of hepatitis C virus outside the liver: evidence from Asia","volume":"37","author":"Younossi","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.numecd.2021.05.019_bib10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1053\/j.gastro.2018.11.022","article-title":"Direct-acting antiviral therapy for HCV infection is associated with a reduced risk of cardiovascular disease events","volume":"156","author":"Butt","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.numecd.2021.05.019_bib11","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/apt.15102","article-title":"Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes","volume":"49","author":"Li","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.numecd.2021.05.019_bib12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jgh3.12474","article-title":"Eradication of hepatitis C virus with direct-acting antivirals improves glycemic control in diabetes: a multicenter study","volume":"5","author":"Takahashi","year":"2021","journal-title":"JGH Open"},{"key":"10.1016\/j.numecd.2021.05.019_bib13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.dld.2015.10.016","article-title":"Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality?","volume":"48","author":"Vanni","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.numecd.2021.05.019_bib14","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1111\/dom.14168","article-title":"Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antiviral therapy: a prospective study","volume":"22","author":"Adinolfi","year":"2020","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.numecd.2021.05.019_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.numecd.2021.05.019_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/hep.31672","article-title":"NAFLD and cardiometabolic risk factors: the liver fibrosis trajectory through the lens of biological interactions","volume":"73","author":"Pirola","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.numecd.2021.05.019_bib17","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41574-019-0316-1","article-title":"Benefit of lifestyle-based T2DM prevention is influenced by prediabetes phenotype","volume":"16","author":"Campbell","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.numecd.2021.05.019_bib18","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(12)60525-X","article-title":"Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study","volume":"379","author":"Perreault","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2021.05.019_bib19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/j.1365-2893.2011.01568.x","article-title":"Assessment of factors associated with pre-diabetes in HCV infection including direct and dynamic measurements of insulin action","volume":"19","author":"Mukhtar","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.numecd.2021.05.019_bib20","first-page":"88","article-title":"Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The task force on diabetes and cardiovascular diseases of the European society of cardiology (ESC) and of the European association for the study of diabetes (EASD)","volume":"28","author":"Ryden","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2021.05.019_bib21","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1016\/j.numecd.2021.04.016","article-title":"Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes","volume":"31","author":"Sasso","year":"2021","journal-title":"Nutr Metabol Cardiovascul Dis"},{"key":"10.1016\/j.numecd.2021.05.019_bib22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.atherosclerosis.2020.01.010","article-title":"Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: a prospective multicentre study","volume":"296","author":"Adinolfi","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2021.05.019_bib23","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.3748\/wjg.v20.i23.7089","article-title":"Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen","volume":"20","author":"Lonardo","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.numecd.2021.05.019_bib24","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1111\/liv.14608","article-title":"Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis","volume":"40","author":"Salomone","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.numecd.2021.05.019_bib25","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000203","article-title":"Hepatitis C virus clearance by direct-acting antivirals agents improves endothelial dysfunction and subclinical atherosclerosis: HEPCAR study","volume":"11","author":"Munoz-Hernandez","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.numecd.2021.05.019_bib26","first-page":"11","article-title":"Liver fibrosis biomarkers accurately exclude advanced fibrosis and are associated with higher cardiovascular risk scores in patients with NAFLD or viral chronic liver disease","author":"Ballestri","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.numecd.2021.05.019_bib27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/fvl.13.11","article-title":"Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges","volume":"8","author":"Lemoine","year":"2013","journal-title":"Future Virol"},{"key":"10.1016\/j.numecd.2021.05.019_bib28","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1111\/jgh.14067","article-title":"Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients","volume":"33","author":"Adinolfi","year":"2018","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321002428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475321002428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:19:20Z","timestamp":1760545160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475321002428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0939475321002428"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2021.05.019","relation":{},"ISSN":["0939-4753"],"issn-type":[{"type":"print","value":"0939-4753"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clearing hepatitis C virus with direct antiviral agents reduces cardiovascular events in patients with prediabetes. Commentary to Sasso and colleagues","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2021.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}